- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone
Alfred L. Garfall, MD, discusses follow-up data from the DREAMM-8 study presented at ASCO 2024.
EP: 1.Unmet Needs in Multiple Myeloma Ahead of ASCO 2024
EP: 2.Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024
EP: 3.MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024
EP: 4.Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024
EP: 5.ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone
EP: 6.Future Directions in the Management of Multiple Myeloma
Video content above is prompted by the following questions:
- Discuss the data presented at ASCO 2024 on the DREAMM-8 study (NCT04484623) of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). (Abstract)
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- N=155
- Median follow-up: 21.78 months
- PFS
- ORR
- Median duration of response
- OS
- Safety
- Please provide your key takeaways from this study.How might these findings impact the management of patients with RRMM?
- Belantamab mafodotin was previously withdrawn from the US market for RRMM following results from the phase 3 DREAMM-3 trial (NCT04162210) which did not meet its primary endpoint of progression-free survival (PFS). How do the results of the DREAMM-8 trial shed light on potential advantages of BPd in patients with RRMM?
Carfilzomib‐Based Quadruplets Challenge VRd as Frontline Multiple Myeloma Backbone
August 21st 2025Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in NDMM.
Read More
On the Path to Greater Precision in Treating Multiple Myeloma
August 18th 2025Past efforts to collect data and to understand the relationship between minimal residual disease and outcomes will allow help researchers in multiple myeloma develop a new generation of targeted therapies, decide when treatment can be stopped, and possibly screen populations for the disease.
Read More
How M-Power Is Building Trust to Raise Awareness of Multiple Myeloma in the Black Community
August 12th 2025International Myeloma Foundation Chief Medical Office Joseph Mikhael, MD, shares how the M-Power initiative is addressing disparities through community engagement, education, and improved clinical trial access.
Read More
